Shockwave Medical (SWAV) has provided an update.
Shockwave Medical, Inc. has entered into a definitive merger agreement on April 4, 2024, to be acquired by Johnson & Johnson. Through this deal, each share of Shockwave common stock will be converted into a cash entitlement of $335.00, and similar cash considerations will be provided for stock options and restricted stock units. The successful completion of the merger hinges on customary conditions, including regulatory approvals and the affirmative vote of the majority of Shockwave shareholders. The transaction is expected to close by mid-2024, and if certain conditions are met, Shockwave may owe Johnson & Johnson a termination fee of $448.0 million. This strategic move is anticipated to drive value for shareholders and integrate Shockwave’s medical technology into Johnson & Johnson’s portfolio.
For an in-depth examination of SWAV stock, go to TipRanks’ Stock Analysis page.
